Prasinezumab (PASADENA / related)
Prasinezumab was studied in early Parkinson’s disease as an anti-alpha-synuclein antibody. It is not a dementia approval.
Overview
Kept as a cited synuclein programme neighbour for Lewy-body biology on this atlas. Parkinson’s results do not equal a dementia label.
Similar pages
not linked directly; found by shared links- TargetAlpha-synuclein
Shares Prasinezumab, Parkinson’s disease dementia and the tag dementia-atlas.
- DiagnosisDementia with Lewy bodies
Shares Prasinezumab, Parkinson’s disease dementia and the tag dementia-atlas.
- TrialTRONTIER 2 (trontinemab Phase 3)
Shares Roche and the tag dementia-atlas.
- TreatmentTrontinemab
Shares Roche and the tag dementia-atlas.
- TreatmentRivastigmine
Shares Parkinson’s disease dementia and the tag dementia-atlas.
- TargetAcetylcholinesterase
Shares Parkinson’s disease dementia and the tag dementia-atlas.
- DiagnosisDementia (umbrella)
Shares Parkinson’s disease dementia and the tag dementia-atlas.
- DiagnosisAlzheimer’s disease
Shares Roche and the tag dementia-atlas.